Answers are grounded in this paper and cite their sources.
Introduction Sarcoglycanopathies comprise a subgroup of four muscular dystrophies characterized by progressive muscle weakness and reduced life expectancy. A major challenge in studying these disorders is the broad heterogeneity observed among patients but also among muscles within the same individual. The biological basis of this heterogeneity remains largely unknown. Here we set out to identify the molecular pathways, genes, and cellular populations that contribute to this differential muscle involvement. Methods We used a β-sarcoglycan knockout (Sgcb KO) mouse model and analyzed nine skeletal muscles from different anatomical regions. We scored fibrosis, regeneration, necrosis, centronucleation, and fiber size variability at 1, 6, and 12 months of age. We performed transcriptomic profiling at one month of age and quantified CD45+ immune infiltration by flow cytometry. In healthy wild-type muscles, we characterized resident macrophage subsets based on TIM4 and CCR2 expression. We then compared the steady-state abundance of each subset with the CD45+ infiltration of the corresponding dystrophic muscle. Results We defined distinct patterns of histological progression across the nine muscles. Severity followed a proximo-distal gradient shaped by muscle size and metabolic identity. Transcriptomic profiling provided an accessible roadmap of early disease. It identified immune pathways, particularly macrophage-associated signatures, as the strongest correlate of muscle-specific disease severity. In healthy muscle, the self-renewing TLF+ (TIM4+/CCR2-) subset varied markedly between muscles. Muscles with a larger TLF+ compartment at steady state tended to develop greater CD45+ immune infiltration under disease. However, this association did not reach statistical significance. Conclusions Together, these findings point to resident TLF+ macrophages as a candidate muscle-intrinsic factor in differential disease susceptibility. They also provide a framework for understanding selective muscle vulnerability in sarcoglycanopathies.
No takes yet. Share an insight, caveat, or question.
Cheli et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: